Neurology: Interstuming stem cells are safe and feasible for treating stroke

Neurology-Interstuming Stem Cells for Stroke Safe and Viable Stem Cell Therapy is an emerging model in stroke therapy, and animal model studies have shown that stem cell transplantation into the brain can improve function.
the STARTING (Stem Cell Application Researches and Trials In NeuroloGy) trial, a randomized controlled trial of intravenously administered fetal bovine serum (FBS)-cultured self-filled stem cells (MSCs), showed that the efficacy of MSC therapy needed to be improved.
, it has been reported that the use of FBS long-term cultured interstitity stem cells and interstital stem cells aging increased and nutritional support decreased.
serum culture obtained during acute stroke to expand mesotoplisic stem cells, which can regulate the release of nutrient factors and microRNA spectrum.
it also enhances post-stroke recovery by increasing the proliferation rate of interstumined stem cells and reducing aging, increasing migration to the infarction brain region, and increasing neurogenesic/angiogenesic.
The University's Jong-Won Chung et al., based on the STARTING-2 trial, explored whether patients with ischemic stroke with moderate and severe defects had better results by injecting intrabody-infused stem cells with intrabody serum amplification than patients receiving standard treatment.
in this RCT, patients with severe cerebral arterial infarction within 90 days of the onset of symptoms were assigned to a pretreated self-treatment MSC injection (MSC group) or a separate standard treatment (control group).
result was a three-month improvement of the Rankin Scale (mRS) score.
secondary result is further evidence of the recovery of the movement.
results showed that a total of 39 and 15 patients were included in the MSC and control groups, respectively, for final intentional therapy analysis (intention-to-treat).
the average age of patients was 68 years (range, 28-83), with an average interval of 20.2 days from stroke to randomization.
baseline characteristics between groups are not different.
3 months, there was no significant difference in msR score transfer between groups (P s 0.732).
But a secondary analysis showed significant improvements in lower limb movement in the MSC group compared to the control group (Motricity index leg score change, p s 0.023), which was noteworthy in patients with low predicted recovery potential.
the entire trial, there were no serious, treatment-related adverse events.
significance of this study is that it has been found that pre-treated intravenously pre-treated in vitro MSCs and autobiographic serums are feasible and safe in patients with chronic severe stroke.
treatment of interstate charge stem cells was not related to the improvement of 3-month MRS score, but was beneficial to the improvement of leg movement function.
original source: Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic StrokeJong-Won Chung, Won Hyuk Chang, Oh Young Bang, Gyeong Joon Moon, Suk Jae Kim, Soo-Kyoung Kim, Jin Soo Lee, Sung-Il Sohn, Yun-Hee Kim, for STARTING-2 collaboratorsNeurology Jan 2021, 10.1212/WNL.0000000011440; DOI: 10.1212/WNL.0000000000011440Freeman Source: MedSci Original Copyright Notice: All noted on this website "Source: Metz Medicine" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here